Metformin: A new oral biguanide

Clinical Therapeutics

Volumn 18, Issue 3, 1996, Pages 360-371

  Campbell, R Keith ^a   White Jr , John R ^b   Saulie, Barbara A ^c  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c College of Pharmacy ^*

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; CHLORPROPAMIDE; CIMETIDINE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; GUAR GUM; INSULIN; LIPID; METFORMIN; NEW DRUG; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CLINICAL ARTICLE; DRUG COST; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRESCRIPTION; REVIEW; WEIGHT GAIN;

EID: 0029938254     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80017-8     Document Type: Article

References (37)

1. American Diabetes Association. Diabetes 1996: Vital Statistics, Alexandria, Va: American Diabetes Association; 1996: 1-102.
2. DeFronzo RA, Ferrannini VA. Insulin resistance: A multifaceted syndrome responsible for NIDDM obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
3. DeFronzo RA, Barzilia N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991; 73:1294-1301.
4. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. NEJM. 1995; 333:541-549.
5. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977-986.
6. American Diabetes Association. Consensus statement on pharmacologic therapy for patients with non-insulin-dependent diabetes mellitus. Diabetes Care. 1995;18: 1510.
7. American Diabetes Association. Medical Management of Non-Insulin-Dependent (Type II) Diabetes. Alexandria, Va: American Diabetes Association; 1994:1-99.
8. Stumvoll M, Hurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. NEJM. 1995;333:550-554.
9. Johnson AB, Webster JM, Sum C-F, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1992;42:1217-1222.
10. Crofford OB. Metformin. NEJM. 1995; 333:588-589.
11. Campbell IW. Metformin and the sulphonylureas: The comparative risk. Horm Metab Res. 1985;(Suppl 15):105-109.
12. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care. 1992;15:539-542.
13. Rossetti L, DeFronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: In vivo and in vitro correlations. Metabolism. 1990;39:425-435.
14. Bailey CL. Biguanides and NIDDM. Diabetes Care. 1992;15:755-772.
15. Krogh CME, ed. Compendium of Pharmaceuticals and Specialties. 28th ed. Ottawa, Ontario, Canada: Canadian Pharmaceutical Association; 1993:506.
16. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 1990;13:696-704.
17. Laulau JD, Andrejak M, Morniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: A study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27:285-288.
18. Dorman TL. Double-blind evaluation of efficacy and tolerability to metformin in NIDDM. Diabetes Care. 1991;14:342-344.
19. Goodman AM, Metformin Investigator Group. Efficacy and safety of metformin in NIDDM: Results of a multicenter trial. Diabetes. 1993;42(Suppl):178. Abstract.
20. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabetic Med. 1990;7: 510-514.
21. Hermann LS, Karlsson J-E, Sjøstrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol. 1991;41:263-265.
22. Rains SGH, Wilson EA, Richmond W, et al. The reduction of low density lipoprotem cholesterol by metformin is maintained with long-term therapy. J R Soc Med. 1989;82:93-94.
23. Montanari G, Bondioli A, Rizzato G, et al. Treatment with low dose metformin in patients with peripheral vascular disease. Pharm Res. 1992;25:63-73.
24. Giugliano D, DeRosa N, DiMaro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16:1387-1390.
25. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44: 107-112.
26. Reaven GM, Johnson P, Hollenbeck B, et al. Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab. 1992; 74:1020-1026.
27. Klein W. Sulfonylurea-metformin-combination vs. sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy: Results of a prospective randomized study in 50 patients. Diabete Metabol. 1991;17:235-240.
28. DeFronzo RA, Goodman A. Combined metformin/glyburide treatment in NIDDM patients not optimally responding to maximum dose sulfonylurea: Results of a multicenter trial. Diabetes. 1993;42(Suppl): 455. Abstract.
29. Hermann LS, Schertsten B, Bitzen P-O, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care. 1994;17: 1100-1109.
30. Bailey CJ. Metformin revisited: Its action and indications for use. Diabetic Med. 1988;5:315-320.
31. Marchetti P, Giannarelli R, di Carlo A, Navalesi R. Pharmacokinetic optimisation of oral hypoglycemic therapy. Clin Pharmacokinet. 1991;21:308-317.
32. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis: Case report and review of the literature. Arch Intern Med. 1992;152:2333-2336.
33. Glucophage package insert. Princeton: Bristol-Myers Squibb Co; Pharmaceutical Division; 1995.
34. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine. Br J Clin Pharmacol. 1987;23:545-561.
35. Reynolds JEF, ed. Martindale: The Extra Pharmacopeia. CD-ROM version. Englewood, Calif: Micromedex, Inc; 1994:83.
36. Melchior WR, Jaber LA. Metformin: An antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother. 1996;30:158-164.
37. Karlsson FO, Garber AJ. Metformin comes to America: What to do now. Clin Diabetes. 1995;13:78-82.